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Preclinical biological and physicochemical evaluation of two-
photon engineered 3D biomimetic copolymer scaffolds for bone
healing
Carina Kampleitnera‡, Katayoon Changib‡, Reda M. Felfelc, Colin Scotchfordc,
Virginie Sottiled, Rainer Klugere, Oskar Hoffmanna, David M. Grantc, Michelle M.
Epsteinb
A major challenge in orthopedics is the repair of large non-union bone fractures. A promising therapy for this indication is
the use of biodegradable bioinspired biomaterials that stabilize the fracture site, relieve pain and initiate bone formation
and healing. This study uses a multidisciplinary evaluation strategy to assess immunogenicity, allergenicity, bone responses
and physicochemical properties of a novel biomaterial scaffold. Two-photon stereolithography generated personalized
custom-built scaffolds with a repeating 3D structure of Schwarz Primitive minimal surface unit cell with a specific pore size
of ~400 µm from three different methacrylated poly(D,L-lactide-co-ε-caprolactone) copolymers with lactide to caprolactone 
monomer ratios of 16:4, 18:2 and 9:1. Using in vitro and in vivo assays for bone responses, immunological reactions and
degradation dynamics, we found that copolymer composition influenced the scaffold physicochemical and biological
properties. The scaffolds with the fastest degradation rate correlated with adverse cellular effects and mechanical stiffness
correlated with in vitro osteoblast mineralization. The physicochemical properties also correlated with in vivo bone healing
and immune responses. Overall these observations provide compelling support for these scaffolds for bone repair and
illustrate the effectiveness of a promising multidisciplinary strategy which could be widely used for the preclinical evaluation
of biomaterials.
Introduction
The repair of large non-union bone lesions may be a major
complication of traumatic injury, metabolic bone disease like
osteoporosis and tumours.1, 2 Synthetic biomaterials have been
developed to fill bone defects and accelerate bone healing1, 3,
because autologous, allogeneic and cadaver bone grafts, which
are the gold standard for bone repair, are associated with a
myriad of complications and limited availability.1, 2, 4, 5 The
limitations of autologous and allogeneic bone grafts can be
overcome by using bone substitutes or synthetic grafts.3 A large
range of osteoconductive and osteoinductive biomaterials have
been considered for bone repair which have potential2 including
bioengineered biodegradable materials that provide structure
within bone lesion and would be replaced by newly formed bone
during bone regeneration.
The biology of bone fracture healing is a multistage process
that follows a specific cascade resulting in unscarred restoration
of bone tissue.6 Local and systemic growth and differentiation
factors, hormones, cytokines and extracellular matrix proteins
interact with cells in the circulation and fracture site7 and begin
with an inflammatory phase, followed by repair and bone
remodeling.8 Transient inflammation after injury is essential6, 9, 10
to produce factors that initiate osteoblast (OB)- and osteoclast
(OC)-mediated bone repair. Bone biomaterials should not induce
chronic inflammation or fibrosis, but should promote mild
inflammation, followed by osteoconduction or induction, provide
mechanical support and degrade over time.11 In the event that
biomaterials induce excessive inflammation and/or immune and
allergic responses, there might be delayed and/or inhibition of
bone repair.12, 13
A porous three-dimensional (3D) scaffold for bone repair
ideally should mimic an autologous bone graft14, be
biodegradable and either induce minimal inflammation or no
inflammation, as long as they are introduced with the factors that
promote bone repair and should not induce fibrosis or scarring.15
Examples of biodegradable polymers that are resorbed over time
frequently used in regenerative medicine16-18 include polyglycolic
acid (PGA), polylactide (PLA), polylactic-co-glycolic acid (PLGA),
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poly-ε-caprolactone (PCL), poly(D,L-lactide) (PDLLA) and 
additional copolymers and composites.19, 20 Although scaffold
degradation is beneficial, undesired effects caused by
degradation products via the formation of small chain carboxylic
acids may change the local pH and cause inflammation21, 22 or in
some cases as occurs within PLA, acidic degradation products
may be toxic.17 Methods that have been developed for the
production of these porous polymeric materials include
electrospinning, phase separation and porogen leaching.
However, these techniques do not enable the manufacture of
complex 3D structures with tunable micro-scale features.
Computer-aided design (CAD) based technologies like 3D-
printing and stereolithography are capable of manufacturing
scaffolds for tissue engineering, but to obtain true biomimetic or
well-defined structures sufficient resolution is required.23 Two-
photon polymerization (TPP) is an example of stereolithography
technology and is capable of fabricating well-defined 3D
microstructures with a resolution of 100 nm.24, 25 For bone filling
scaffolds, the optimum pore size ranges from 200 to 400 µm,
which is similar to the average size of human osteon (~223 µm).26
Moreover, it is possible to design and produce customizable
scaffolds that are compressible and tailored to fit into the
fracture site. One limitation in the past for TPP has been the slow
scan speeds but as the technology improves exciting capability is
now available to deliver high resolution scaffolds in commercially
attractive timescales.
In this study, methacrylated poly(D,L-lactide-co-ε-
caprolactone) (PLCL) copolymers of different compositions and
chain lengths (LCM3 (16:4), LCM4 (18:2) and LCM6.1 (9:1)),
where numbers represent monomer units of lactide (LA) and
caprolactone (CL) were used to generate biomimetic 3D Schwarz
Primitive (P) minimal surface scaffold structures with a pore size
of 400 µm.27, 28 Here, we combine materials science, bone biology
and immunology to establish a strategy for evaluating these
developed TPP-engineered copolymer scaffolds for eventual use
in patients. Our approach includes 1) an in vitro evaluation of
osteoblast and osteoclast function and an in vivo mouse calvarial
defect model to assess bone healing in the context of the
scaffolds, 2) in vitro degradation and mechanical studies
(compressive strength and modulus), and 3) in vitro and in vivo
evaluation of inflammatory, immune and allergic reactions to
biomaterials including an in vitro assay providing information on
antigen crossreactivity and cytotoxicity; a rapid high-throughput
intraperitoneal assay providing data on the inflammation and the
cytokine milieu; and a sub-chronic subcutaneous long-term assay
providing information on the longevity of the inflammatory
response and the capacity of the biomaterial to induce fibrosis.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
guidelines for the Care and Use of Laboratory Animals of the
Austrian Ministry of Science. The protocol was approved by the
Committee on the Ethics of the Austrian Ministry of Science (No:
66:006/00 12-11/3b/2012). All painful procedures were
performed under anesthesia, and all efforts were made to
minimize suffering.
Mice
Female 8-12 week old BALB/c and C57BL/6 (B6) mice (Charles
River Laboratories, Sulzfeld, Germany) were used for in vivo
experiments. Neonatal mice were used for the isolation of OBs.
The mice were housed in the mouse facility at the Department of
Pharmacology and Toxicology, University of Vienna, Vienna,
Austria. Mice were provided food (Ssniff Spezialdiäten GmbH,
Soest, Germany) and tap water ad libitum.
2D copolymer disk and 3D scaffold production
LCM scaffolds were produced and provided by the Institute for
Bioprocessing and Analytical Measurement Techniques (iba,
Heiligenstadt, Germany) and the detailed description of the
methodology can be found in.27 Briefly, methacrylated PLCL
copolymers were synthesized by ring opening polymerization.
Three different LA/CL ratios were used and coded LCM3 (16:4),
LCM4 (18:2) and LCM6.1 (9:1). Both LCM4 and LCM6.1 have the
same molar ratio (LA/CL) of 18:2 and 9:1 respectively compared
to LCM3 which is 16:4. However LCM6.1 has lower molecular
weight (1059 g mol-1) than LCM4 (1822 g mol-1) and LCM3 (1742
g mol-1).29
For disk manufacturing, precursor-LCMs and photoinitiator
(Irgacure369 (0.1 wt.%), BA740 (0.2 wt.%)) were filled into a
silicon mold (Ø= 5 mm, 0.5 mm height) and solidified by 9 min of
UV irradiation (Vacuum-UV-Exposure Box2, proMa). The polymer
disks were developed in acetone for 7 days before drying under
vacuum and sterilized using gamma irradiation at the dose of 25
± 2.5 kGy and kept in sterilization pouches prior to use. For 3D
scaffold manufacturing, photoinitiator and LCM precursors
underwent polymerization with a TPP apparatus (M3DL, LZH
Hannover, Germany) with a femtosecond laser source (140 fs, 80
MHz, 800 nm) to produce LCM scaffolds followed by washing in
acetone to remove the unpolymerized precursors. The produced
repeating array of Schwarz P unit cell (with 400 µm size) scaffolds
were sterilized using gamma irradiation as described above.
Table 1: Structural properties of the produced LCM scaffolds,
published in the authors’ pervious paper29, the table also shows
the percentage of weight change of the scaffolds as wet at the








(%) after ~ 12
weeks in vitro (in
PBS at 370oC)
LCM3 314 ± 14 177 ± 7 214
LCM4 328 ± 26 177 ± 10 252
LCM6.1 290 ± 25 152 ± 7 121*
* wet weight change of LCM6.1 scaffold was recorded after 69
days.
In vitro bone cultures
Osteoclasts
To study effects on osteoclastogenesis, we performed a co-
culture model using primary mouse OB and bone marrow OC
precursors as previously described.30 Primary mouse OBs were
isolated from neonatal mouse calvarial bones using an enzymatic
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digestion.31 These OBs (6.2 x 104 cells/cm2) were cultured
together with bone marrow OC precursors harvested from
mouse femurs and tibiae in αMEM (Gibco, Thermo Fisher 
Scientific, Vienna, Austria), 10% heat-inactivated fetal bovine
serum (FBS, Gibco), 1% penicillin/streptomycin (Gibco), 1 nM
1,25-(OH)2-vitamin D3 (Sigma-Aldrich, Vienna, Austria) and 1 µM
prostaglandin E2 (PGE2, Cayman Chemicals, Hamburg, Germany)
onto 96-well culture plates containing the copolymer disks (Ø = 5
mm) or onto tissue culture plastic at 37°C and 5% CO2. At day 6
of co-culture, histochemical staining for tartrate-resistant acid
phosphatase (TRAP) was done to characterize OCs. Cells were
fixed in 3.7% buffered formaldehyde (Carl Roth, Vienna, Austria)
at RT and stained with naphthol AS-BI phosphate (Sigma-Aldrich),
fast red violet salt (Sigma-Aldrich) and 10 mM sodium tartrate
(Sigma-Aldrich). TRAP+ multinucleated cells (TRAP+ MNCs) with
3 or more nuclei were considered mature OCs and enumerated
under a light microscope (Nikon Diaphot 300).
Osteoblasts
Primary mouse OBs (6.2 x 104 cells/cm2) were seeded in αMEM, 
10% FBS and 1% penicillin/streptomycin onto 96-well culture
plates containing the 2D copolymer disks (Ø = 5 mm) or onto
tissue culture plastic at 37°C and 5% CO2. To induce OB
differentiation, culture medium was supplemented with 50
µg/ml ascorbic acid (Sigma-Aldrich) and 5 mM β-
glycerophosphate (Sigma-Aldrich) 24 h post seeding. OBs
cultured in medium alone served as control group. OB cell
proliferation was evaluated by “Presto Blue cell viability assay”
(Molecular Probes, Thermo Fisher Scientific, MAN0003232)
according to the manufacturer`s instructions. Briefly, cells were
incubated with Presto Blue reagent and the reagent was reduced
by metabolically active cells. This serves as an indicator for cell
viability and proliferation. The reduction product was detected at
560/590 nm. At day 7, alkaline phosphatase (ALP) activity was
measured as a marker for OB differentiation from cell lysates with
a fluorogenic substrate (6,8-difluoro-4-methylumbelliferyl
phosphate, DIFMUP, Molecular Probes, Thermo Fisher Scientific)
at 388/455 nm as previously described.32 In addition, ALP activity
was detected using SIGMAFAST™ BCIP®/NBT substrate stain
(Sigma-Aldrich) according to the application note of PromoCell
(Heidelberg, Germany). Calcium deposition of mature OBs was
visualized by Alizarin Red S (ARS) and von Kossa staining at day
14. For ARS staining, cells were fixed in 10% neutral buffered
formalin (Sigma-Aldrich) and stained with 40 mM ARS (pH 4.2)
(Sigma-Aldrich). Quantification of ARS-stained cultures was
performed by a cetylpyridinium chloride extraction method and
extracts were read at 520 nm. For von Kossa staining, cells were
fixed in 10% neutral buffered formalin (Sigma-Aldrich) and
incubated with 5% silver nitrate solution (Sigma-Aldrich) under
UV light before neutralization with 5% sodium thiosulfate (Sigma-
Aldrich). All stained plates were scanned on a high-resolution flat-
bed scanner (Epson Perfection 1200Photo).
In vivo intracalvarial defect model
The LCM scaffolds (4 mm diameter) were incubated overnight
in sterile PBS. Orthovita Vitoss™ Foam (Vitoss, Malvern, USA) was
used in the experiments as a positive control. Vitoss was cut into
4 mmdiameter and then soaked in 50 µl PBS before implantation.
Non-healing critical, full-thickness size defects were created in
anesthetized (100 mg/kg ketamine (Ketamidor®, Richter Pharma,
Wels, Austria) and 5 mg/kg xylazine (Rompun®, Richter Pharma))
12-week old female BALB/c mice (n=5-6) in the right parietal
bone using a dental trephine with 4 mm diameter under constant
irrigation while preserving the underlying dura mater. LCM
scaffolds or Vitoss were implanted into the defect or left empty
and then the skin was sutured. The animals were monitored post-
op and treated with 0.1 mg/kg buprenorphine (Bupaq®, Richter
Pharma) for analgesia every 10-12 h for 3 days. At 12 weeks post
operation, the animals were sacrificed by cervical dislocation,
skulls were harvested and fixed in 4.5% buffered formalin (Carl
Roth). For histological examination, light-curing resin (Technovit
7200 VLC + BPO, Heraeus Kulzer, Wehrheim, Germany)
embedded undecalcified sections (80-100 µm) were prepared
parallel to the sagittal suture with an Exakt Cutting and Grinding
Equipment (Exakt, Norderstedt, Germany) and stained with Levai
Laczko dye according to a standardized method.22
Immunological assessment
In vivo immunological assessment of scaffolds
The LCM scaffolds (2 mm3) were incubated overnight in sterile
PBS. Vitoss was used in all immunological experiments as a
positive control because it contains type I bovine collagen, which
is recognized as a foreign protein and generates an immune
response in mice. Vitoss was cut into 2 mm3 and then soaked in
50 µl PBS before implantation. Scaffolds and Vitoss were
implanted either intraperitoneal (i.p.) or subcutaneous (s.c.) into
8-week old female BALB/c and B6 mice (n=5-8) and compared to
age-matched sham controls. For implantation, mice were
anesthetized with 100 mg/kg ketamine (Ketanest®, Pfizer
Corporation Austria GmbH., Vienna, Austria) and 6 mg/kg
xylazine (Rompun®, Bayer AG, Leverkusen, Germany).
For the high throughput model, we used the implantation
approach described in33 and.34 Abdominal fur was shaved and
cleaned with 70% alcohol and polyvidone iodine (Betadine®).
Using aseptic techniques, an 8 mm midline incision was made
along the linea alba followed by an incision in the peritoneum.
LCM scaffolds or Vitoss were placed in the peritoneal cavity. The
abdominal muscles and skin were sutured with absorbable 4-0
Vicryl suture (Ethicon Inc., Somerville, USA) and 4-0 nylon suture
(Ethicon), respectively. The same incision and suture were used
without implanting materials for the sham controls. The
peritoneal cavity was lavaged 7 days after implantation with 3 ml
PBS and peritoneal cells were counted and peritoneal fluid was
stored at -20°C until thawed for the measurement of IL-1β 
(eBioscience Inc., San Diego, USA), IL-2 and IL-4 (ELISA MAXTM
Standard, Biolegend, San Diego, USA) cytokines.
For the subchronic model, we used the implantation approach
described in33 and.35 An 8 mm midline abdominal incision of the
skin along the linea alba was made under aseptic conditions. LCM
scaffold or Vitoss of the same size (2 mm3) or no materials were
inserted s.c. and then the skin was closed with 4-0 nylon suture.
The mice were monitored until recovery from anesthesia. At 12
weeks, the implantation site with surrounding tissue (10 mm2)
from each mouse was excised and fixed in 4% formaldehyde
overnight and then embedded in paraffin. Tissue sections (4 μm) 
were prepared and stained with Hematoxylin and Eosin (H&E)
and Masson's trichrome (Sigma-Aldrich).
In vitro splenocyte responses to scaffolds
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LCM copolymer disks (Ø= 5 mm) were incubated with BALB/c
and B6 mouse splenocytes. Spleens were minced and passed
through a sterile 40 µm cell strainer (Corning Life Sciences,
Durham, USA) in cold sterile PBS. The cells were centrifuged and
RBCs were lysed with lysis buffer (BD Pharm Lyse™, BD
Bioscience, New Jersey, USA). Titrated numbers of splenocytes
were suspended in RPMI with 10% FBS, 1%
penicillin/streptomycin, 0.1% gentamicin (Gibco), 0.2% ß-
mercaptoethanol 50 mM (Gibco) and 1% (100x) non-essential
amino acids (Gibco) and were incubated with the copolymer
disks, Vitoss, 10 µg/ml Concanavalin A (ConA, Amersham
Pharmacia Biotech, Piscataway, USA) or a combination of ConA
and biomaterials in a 96-well plate at 37°C at 5% CO2 for 72 h. Cell
proliferation was measured using a cell proliferation ELISA BrdU
kit (Roche Diagnostics, Vienna, Austria) by adding BrdU at 48 h
and measuring absorbance at 450 nm at 72 h. In addition,
supernatants were removed at 72 h and stored at -20oC until
thawed for the ELISA measurements of IL-1β, IL-2, IL-4 and IFNγ 
(ELISA MAXTM Standard, Biolegend, San Diego, USA).
Scaffold degradation studies
The degradation study was performed for LCM scaffolds of
dimensions 2 mm3 according to the standard BS EN ISO 10993-
13:201036. The high reproducibility of the method due to the TPP
production allows individual scaffolds to be followed through
their degradation pathway27. Scaffolds were placed individually
into glass vials containing 30 ml PBS (pH = 7.4 ± 0.2) solution and
maintained in an oven at 37oC. At various time points the
specimens were extracted with tweezers, placed into empty vials
and dried in a vacuum oven (Medline Scientific, UK) at 50°C for
60 min. Afterwards, the dry weight of the scaffolds was recorded
and samples were then returned back to vials containing fresh
PBS. The percentage mass loss (ML) at each time point was




ቁൈ ͳͲͲሺΨሻ where md is the mass of the
degraded scaffold after drying at 50°C in the vacuum oven for 60
min and mi is the initial dry mass of the scaffold.
Optical images of dried LCM scaffolds were captured at each
degradation time point using a Nikon digital camera (Dxm1200F,
Japan) attached to Nikon microscope (Japan). The images were
processed using image analysis software (Nikon ACT-1 v. 2.62,
LEAD Technologies, USA).
Mechanical test
The compressive strength and modulus were determined using
Hounsfield tester and the calculations were done according to
the standard ASTM 1621-10: 2010.37 Scaffolds were inserted
vertically between two flat plates of the testing machine where
the load was applied on the cross section of the scaffold. A
crosshead speed of 0.5 mm/min and a 5 N load cell was used and
the test was carried out up to 20% strain (below the yield strain
of the specimens) to obviate permanent deformation within the
scaffolds. At various time points, the specimens were removed
from PBS and dried in a vacuum oven at 50°C for 60 min before
testing. The measurements were applied on dry scaffolds and
carried out in three successive cycles with a time interval of 10
min to permit scaffold recovery. The compressive strength is
taken as the maximum stress at 20% strain, while compressive
modulus was determined as the gradient of the linear portion of
stress-strain curve. The samples were then placed back in the
medium until the next time point.
Statistical analysis
Statistical analysis of biological assays was done using one-way
analysis of variance (ANOVA) with Tukey´s post hoc test for
multiple comparison (GraphPad Prism v 5.0, San Diego, USA). p
values were considered significant at < 0.05.
Results
In vitro assessment of OC and OB differentiation and
maturation
To determine the effect of scaffolds on OC differentiation, OBs
and bone marrow OC precursors were co-cultured in the
presence of LCM3, 4 and 6.1 scaffolds and the medium alone (M)
control group (Fig. 1A). The OC morphology differed between the
M control and LCM3, 4 and 6.1 scaffolds with a high number of
differentiated mature multinucleated TRAP+ OCs (≥ 3 nuclei) in 
the M controls whereas the LCM scaffolds induced fewer, smaller
and less spread out, irregularly-shaped mature OCs. TRAP+
multinucleated OCs for the M group was 8.34 ± 0.87 /mm2 and
for the scaffolds were LCM3: 7.01 ± 1.39 /mm2, LCM4: 9.47 ± 0.90
/mm2 and LCM6.1: 3.74 ± 1.17 /mm2 (Fig. 1B). LCM3 and M
controls induced a similar number of differentiated TRAP+ OC
compared to LCM4, though only LCM4 was statistically
significantly higher compared to LCM6.1 (p<0.01). These data
demonstrate that LCM6.1 significantly reduced OC
differentiation compared to the other tested groups.
To determine the effect of LCMs on OBs, the OB viability and
proliferation was evaluated using the Presto Blue assay. The OB
proliferation peaked at day 3 in the presence of the scaffolds (Fig.
2A) and was significantly higher for LCM3, 4 and 6.1 compared
with osteogenic medium (OM) controls. The OB proliferation
increased minimally and remained stable for the OM controls
over the 14-day culture period. In contrast, LCM3 induced
proliferation from day 1 to day 3 that remained stable until day
14, whereas LCM4 and LCM6.1 increased proliferation initially
followed by decreased proliferation after day 7 with a more
prominent reduction for LCM6.1. These data demonstrate that
there were more proliferating OBs in the presence of LCM3
compared with LCM4 and LCM6.1.
Figure 1: Scaffold-induced in vitro OC differentiation and
maturation. Mouse OC differentiation was determined at day 6 of
co-culturing mouse OBs and bone marrow OC precursors in the
presence of 1,25-(OH)2-vitamin D3 and PGE2. (A) Representative
images show TRAP+ MNCs for medium (M) control group, LCM3, 4
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and 6.1. (B) Endpoint analysis of TRAP+ MNCs. Graph shows the
absolute count of TRAP+ MNCs (≥ 3 nuclei) per mm2 (mean ± SEM,
n=6). **p<0.01.
Figure 2: Scaffold-induced in vitro OB differentiation and
maturation. (A) OB proliferation was determined on days 1, 3, 7, 10
and 14 by Presto Blue assay upon incubation with either medium
alone (M) ●, osteogenic medium (OM) ■, LCM3 △, LCM4 ▽ and
LCM6.1 ◇ illustrated by relative metabolic activity. Relative
metabolic activity is demonstrated as fold increase or decrease
calculated from fluorescence units and normalized to day 1 within
each group (mean ± SEM; n=4-6). day 3: LCM3 and 6.1 vs. OM
*p<0.05, LCM4 vs. OM **p<0.01, day 1: M vs. OM *p<0.05, LCM3 vs.
LCM6.1 ***p<0.001, LCM3 vs. LCM4 **p<0.01 (B) OB differentiation
was assessed by ALP activity at day 7. Representative images
illustrate ALP+-stained cultures. (C) ALP activity was quantified from
cell lysates (day 7) normalized to the growth area (µM DIFMU/mm2,
mean ± SEM, n=6). ***p<0.001 (D) OB mineralization was detected
by calcium deposits at day 14. Representative images show
mineralized matrix visualised by ARS and von Kossa stains. (E)
Mineralization was quantified from ARS-stained cultures by a
cetylpyridinium chloride extraction method (day 14) shown as the
concentration of ARS normalized to the growth area (ARS µM/mm2,
mean ± SEM, n=5-6). ***p<0.001.
To analyze OB differentiation, cells (Fig. 2B) were stained and
the ALP activity was measured (Fig. 2C). The OBs differentiated
normally into more mature OBs and had higher ALP activity in the
OM compared to M control alone (Fig. 2B, 2C). In Fig. 2B, the
number of stained ALP+ cells was increased in all groups
compared to controls without mineralization medium. However,
the staining pattern exhibited when the cells were on LCM disks
differed from the OM controls. Nevertheless, when we quantified
the ALP activity in OBs, no statistical difference in ALP activity
between OM and LCM groups was observed.
To assess OB mineralization, cultured OBs were stained with
ARS and von Kossa. LCM6.1 and LCM4 induced higher
mineralization compared with LCM3 and OM samples as shown
in the tissue culture plate wells (Fig. 2D) and by absorbance of the
extracted ARS calcium complex measurements (Fig. 2E). These
data show that LCM4 and LCM6.1 disks supported higher matrix
mineralization than LCM3.
In vivo evaluation of the bone response to LCM scaffolds
To evaluate the ability of the scaffolds to integrate into the
calvarial bone defects, the three individual LCM scaffolds were
inserted into the empty calvaria and the scaffold structure and
surrounding tissue histologically (Fig. 3) were examined after 12
weeks. In the sham (empty defect) control, a thin layer of fibrous
tissue was observed over the entire defect but with an absence
of bone or foreign materials. In contrast, when Vitoss (β-
tricalcium-phosphate) was implanted, there were agglomerates
and remnants of Vitoss bridging the defect area (visible in black).
On high power field, it appears that Vitoss induced a dense
fibrous tissue with some blood vessels and few inflammatory
cells without evidence of new bone formation. Post implantation
of 3D LCM scaffolds, no new bone formation was observed, but a
significant difference in the structure of the scaffolds (scaffolds
are blue in the bone sections). The LCM3 scaffold has an intact
porous structure with loose connective tissue within the pores
containing inflammatory cells and blood vessels. LCM4 also
contains loose connective tissue, inflammatory cells and blood
vessels, but is smaller and thinner than LCM3 despite having the
exact same size at implantation. In contrast, LCM6.1 appears to
be separated into 2 layers and contains less connective tissue,
inflammatory cells and blood vessels within the pores compared
with LCM3 and 4 scaffolds. Because there was no bone formation
observed, no quantitative bone evaluation was done. Thus, the
raw results are shown in histological sections.
Figure 3: In vivo evaluation of scaffolds in a calvarial defect model.
Non-healing critical-sized calvarial defects were created in 12-week
old female BALB/c mice by a 4 mm dental trephine. Treatment
groups included sham control (empty defect), defects treated with
Vitoss and the different LCM scaffolds. Representative histological
sections were prepared 12 weeks post implantation. Formalin fixed
tissue was embedded in Technovit 7200 and sections (80-100 µm)
were stained with Levai Laczko. Photomicrographs are shown at low
(left) and high (right) magnifications. Black triangles indicate the
bone defect; S: Scaffold; V: Vitoss.
Immunological responses to biomaterials
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To assess the immunological responses to the biomaterials,
both in vivo and in vitro responses were tested. Firstly, a high
throughput in vivo model was used for rapid screening of immune
responses by implanting LCM scaffolds i.p. and measuring the
cellular response and production of IL-1β, IL-2 and IL-4 (Fig. 4). In 
the negative sham control, less than 2 x 106 cells were observed
and were predominantly peritoneal macrophages, with few
eosinophils, lymphocytes, or neutrophils. In contrast, the positive
Vitoss control had more than 4 x 106 cells which included a
significant increase in macrophages, eosinophils and
lymphocytes. All the LCM scaffolds generated minimal
inflammatory responses that were similar to the sham control
(Fig. 3A). These results were mirrored by the cytokine production
with baseline values for IL-1β, IL-2 and IL-4 in the peritoneal fluid 
(Fig. 4B) whereas Vitoss significantly increased IL-1β and IL-4 
compared to the sham controls in B6 and BALB/c mice,
respectively.
To assess whether the LCMs induced inflammatory or fibrotic
changes upon implantation, a subchronic model was used to
examine histological sections for evidence of inflammation,
foreign body giant cells (FBGCs) and fibrosis 12 weeks after
implantation. The LCM scaffolds were compared to both the
minimal inflammation in the sham control and the moderate
response with FBGCs in response to Vitoss (Fig. 5). LCM3 and
LCM4 induced mild inflammation without FBGCs compared to a
more intense response observed with the LCM6.1 scaffolds.
Figure 5 illustrates that Vitoss induced more collagen deposition
compared with LCM3 and LCM4, which had collagen fibers
around degraded scaffold filaments and more collagen was
observed to be present in the LCM6.1 implantation site.
Figure 4: Scaffold evaluation in a rapid high throughput mouse
model. Female BALB/c and B6 mice were implanted i.p. with either
LCM scaffolds, Vitoss, or no materials (sham). Seven days later, mice
underwent peritoneal lavage. The lavage fluid was analyzed (A) for
type and number of inflammatory cells (data are presented as mean
cell counts ± SEM) and (B) for cytokine concentrations (data are
presented as mean cytokine concentrations pg/ml ± SEM). These
data are representative of two independent experiments (n=5).
*p<0.05, **p<0.01 and ***p<0.001 is considered significant
compared to sham.
To determine whether the in vivo responses could be predicted
by an in vitro assay, BALB/c and B6 splenocytes were incubated
with LCM3, LCM4 and LCM6.1 scaffolds or Vitoss and then IL-1β, 
IL-2, IL-4 and IFNγ production and cell proliferation (Fig. 6) were 
measured. When the splenocytes were incubated with medium
alone or in the presence of LCM scaffolds and Vitoss, cytokine
secretion and cell proliferation were similar. However,
Figure 5: Evaluation of scaffolds in a subchronic mouse model.
Female BALB/c mice were implanted s.c. with either LCM scaffolds,
Vitoss, or no materials (sham). At 12 weeks after implantation, skin
from the implantation sites were incised and stained with H&E and
Masson’s Trichrome to evaluate wound healing and fibrosis.
Photomicrographs of stained skin sections are shown at 10x and are
representative of two independent experiments (n=5). Arrows
indicate FBGCs around the implant. *denotes degraded scaffolds.
in the presence of the mitogen, ConA, there is an expected
increase in cell proliferation and cytokines for medium, Vitoss,
LCM3, LCM4 and LCM6.1. There were minor differences in the
magnitude of the responses between mouse strains, with the
most evident difference being a higher BALB/c vs. B6 IL-4
response. Thus, the in vitro studies were predictive of the in vivo
assay, though unable to provide information about chronicity of
inflammation and capacity to induce fibrosis.
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Figure 6: Scaffold-induced in vitro cytokine production and cell
proliferation. BALB/c and B6 splenocytes were cultured in the
presence of LCM scaffolds or Vitoss. Cell proliferation, IL-1β, IL-2, IL-
4 and IFN-γ were measured upon incubation with either medium 
alone ●, ConA ○, Vitoss ■, Vitoss + ConA □, LCM3 ▲, LCM3 + ConA
△, LCM4 ▼ , LCM4 + ConA ▽, LCM6.1 ◆, LCM6.1 + ConA ◇ at 37°C
for 72 h. Proliferation results are presented as the mean of triplicate
samples (BrdU (450 nm) absorbance ± SEM) in the BrdU assay and
the mean of duplicate samples (pg/ml ± SEM) for cytokine
concentration from two independent experiments. *p was
considered significant at <0.05 for biomaterials vs. medium and
biomaterials + ConA vs. ConA alone.
In vitro degradation and mechanical performance
In an attempt to determine whether physical properties of the
scaffolds could correlate with the biological findings, the
degradation and mechanical performance of the LCM scaffolds in
vitro was explored. Figure 7A shows the change in mass loss and
pH of LCM3, LCM4 and LCM6.1 scaffolds with respect to time
throughout degradation in PBS at 37°C for up to 83 days. Mass
loss profiles for all scaffolds showed a two-stage linear increase
with mass loss increased initially at a lower rate up to 28 days and
followed by a more rapid rate until day 90. At the end of
degradation experiment, LCM3 showed lower mass loss (ca. 24%)
in comparison with LCM4 and LCM6.1 (ca. 30 and 36%
respectively). The pH of the degradation medium, PBS, remained
neutral for all specimens at approximately 7.4 ± 0.1 until the end
of degradation period at 90 days. The integrity of the scaffolds
was traced during degradation by imaging at all time points using
4x magnification (Fig. 7B). LCM3 and 4 scaffolds remained intact
until the end of the degradation study at day 90, whereas LCM6.1
collapsed at day 69.
Figure 7: Evaluation of copolymer degradation profile. (A) Change
in mass loss and pH of degradation medium against time during
degradation of LCM3 (blue triangle), LCM4 (red triangle) and LCM6.1
scaffolds in PBS at 37°C. Scaffolds have dimensions of 2 mm3. Error
in mass loss measurement is less than 1% and contained within the
symbol. (B) Integrity of the LCM scaffolds throughout in vitro
degradation in PBS at 37°C. Optical images were taken at all time
points using 4x magnification. Scaffolds have dimensions of 2 mm3.
The change in the image colour was due to change of the microscope
camera during the study.
Change in compressive modulus and strength of LCM3, 4 and
6.1 scaffolds vs. degradation time is shown in Figure 8.
Compressive moduli for LCM3, LCM4 and LCM6.1 scaffolds were
ca. 0.18, 4.4 and 5.5 MPa, respectively before degradation.
Compressive strengths at 20% strain for LCM4 and LCM6.1
scaffolds were more than 15 times higher than LCM3 (0.06MPa).
No changes were seen in both strength and modulus for all
scaffolds over 85 days of degradation in PBS at 37oC.
Discussion
The overall goal of this study was to evaluate the biological and
physicochemical characteristics of novel customizable,
biodegradable, biomimetic TPP-generated LCM copolymers as
support scaffolds for bone fracture healing. We assessed the PLCL
LCM3, LCM4 and LCM6.1 copolymers using in vitro and in vivo
models and found an evident influence of the copolymer
composition in all tests. The LCM6.1 scaffold reduced OC
differentiation and OB proliferation compared with LCM3 and 4,
while OB differentiation was similar for all scaffolds in vitro. LCM3
was more effective in the early stages of bone healing in the
calvarial defect model than LCM4 and LCM6.1. In the in vitro
splenocyte assays, all LCMs were immunologically inert. LCM3
and LCM4 scaffolds were well tolerated in the in vivo assays,
though LCM6.1 induced more intense inflammation and fibrosis
comparably in the subchronic mouse model. In in vitro
degradation studies, LCM4 and LCM6.1 compared to LCM3
scaffolds had faster degradation rates and reduced mechanical
retention. Our study demonstrates that TPP-generated LCM
copolymer scaffolds, especially LCM3 with a lactide to
caprolactone monomer ratio of 16:4 performs well in all tests.
Overall, our results emphasize that polymer composition
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determines physical and biological properties and that these
characteristics correlate. Our combined bone, immunological and
physiochemical tests exemplify the benefit of a multidisciplinary
strategy for preclinical evaluation of novel biomaterials for bone
regeneration.
Figure 8: Evaluation of mechanical properties. Retention of (A)
compressive modulus and (B) compressive strength for LCM3 (blue
triangle), LCM4 (red triangle) and LCM6.1 (green diamond) scaffolds
vs. degradation time. Compressive strength was determined as the
maximum stress at strain of 20%. The measurements were done 3
times and presented as MPa ± SD. Scaffolds have dimensions of 2
mm3.
The innovative TPP microfabrication technology was used in
manufacturing LCM scaffolds due to the ability to produce 3D
polymeric microstructures of almost any desired complexity on
the basis of computer models and form features of
approximately 100 nm. The Schwarz P unit cell minimal surfaces
have high stability at low weight38 and larger fluid permeability in
comparison to other pore structures geometries.39 The Schwarz
P structure is especially useful because it consists of channels and
pores resembling cancellous bone which allows cell migration.
Scaffolds are structures designed to provide stability and to
guide new bone formation. To determine the effect of LCM3, 4
and 6.1 scaffolds on bone repair, these materials were tested in
a calvarial defect model in mice and it was found that the
scaffolds alone did not induce new bone formation. Our findings
support previous studies using a rat calvarial model40 and a
mandibular defect repair model in rabbits with PLGA scaffolds.41
Moreover, we predicted this result because for normal bone
healing additional osteoinductive stimuli are necessary.42
However, the scaffolds, compared to the sham controls, were
associated with more early stage angiogenesis and tissue repair
suggesting minimal bone repair in response to LCM3, 4 and 6.1
scaffolds.
There were two characteristics differentiating LCM3 and LCM4
from LCM6.1: After 12 weeks, LCM3 and 4 scaffolds were 1)
thicker and 2) were associated with more cellular infiltrates than
LCM6.1. A possible explanation for these observed differences
may be due to degradation (thinning and fracturing of the
scaffold of LCM6.1 in histological sections) and potential toxic
degradation products leading to reduced cellular infiltration.
These results are supported by the findings that there was
accelerated degradation of LCM6.1 during in vitro degradation
studies and the finding that LCM6.1 was associated with a
different immune response compared to the other scaffolds.
Taken together, data from in vivo and in vitro biological studies
correlate with in vitro degradation studies.
While the LCM scaffolds did not induce bone formation in our
calvaria model, it is important to note that Vitoss, a commercially
available bone substitute material, did not induce new bone
either. In support of this finding, Barbiere et al. implanted Vitoss
in combination with Bioglass granules in a canine intraspinous
implantation model and showed no bone formation.43 In
contrast, however, in both a mouse ectopic bone formation
model and in a rabbit critical defect femur model, Vitoss has been
reported to induce bone formation.44, 45 There are several
possible explanations for these contradicting data including the
animals, e.g., mouse vs. rabbit and differences between the
protocols. For example, one possibility is that bone healing rates
differ between long bone and calvarial bone. Another possible
explanation is that in the ectopic model, the skin provides a more
reactive environment, e.g., contains more inflammatory and
other mediators promoting bone formation than in the
calvarium. It is also possible that based on studies of clinical
traumatic fractures, Vitoss works optimally because of the
inflammatory environment in the injured site that provides
mediators essential for bone repair.44 This differs substantially
from the calvarial implantation site in this study, which was
almost free of blood and thus, lacks circulating and local
inflammatory mediators that might explain the lack of bone
formation with Vitoss.
The in vivo bone repair studies indicated that early stages of
repair occurred with differences between the LCM scaffolds
tested. To further understand the LCM effects observed in vivo,
we assessed the cellular response to the LCMs by investigating in
vitro OB and OC responses. All the scaffolds increased OB
proliferation compared with OM controls. However, only LCM3
resulted in a sustained increase in proliferation with comparably
much less for LCM6.1. In vitro data show that LCM6.1 reduced OB
proliferation and OC differentiation, whereas LCM6.1 > LCM4 >
LCM3 increased OB mineralization while there was no influence
by any scaffold on ALP activity at the time point measured. The
difference in mineralization may be ascribed to the huge disparity
in the compressive moduli of the scaffolds, LCM6.1 and 4
scaffolds are more than an order of magnitude higher than LCM3
(0.18 MPa). This finding supports the previous study on 3D
hydrogel scaffolds with moduli ranged from 0.01 MPa to 0.3 MPa,
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which concluded that as the modulus increased to ca. 0.23 MPa,
a significant increase in OB mineralization was observed.46 These
results also support a previous study with poly(L-lactic acid) that
showed changes in OC differentiation.47 Interestingly, the
mechanical stiffness of the scaffolds (LCM6.1 > LCM4 > LCM3)
appears to correlate with in vitro findings and supports previous
studies showing that stiff- more than soft- substrates influenced
OB differentiation and osteogenesis48-50, suggesting that
increased mechanical stiffness modulates cell attachment,
proliferation and differentiation. Remarkably, in vitro responses
did not predict the outcome of in vivo bone repair which was also
observed by other groups summarized in a review51 and might be
because the duration of the in vivo experiments (weeks) was
longer than in vitro incubation periods (days), or because the
LCMs are hydrophobic and could lead to the OBs taking longer to
achieve confluence compared to cultures with osteogenic
medium without scaffolds. Additional explanations may be
related to the increased mass loss due to degradation of LCM4
and 6.1, compared with LCM3 (Fig. 7), resulting in increased
degradation products influencing mineralization, or even the
experimental conditions used. For example, in vitro
differentiation is done with medium containing ascorbic acid and
β-glycerophosphate to induce collagen production and promote 
differentiation to mature mineralizing OBs, whereas, there is no
stimulation of osteogenesis in vivo because the scaffolds are not
osteoinductive.
The early phase of bone healing is enhanced with an
inflammatory microenvironment without chronic and aggressive
inflammation, immune or allergic responses that may lead to
reduced bone healing.13 To assess immunogenicity and
allergenicity of the scaffolds, we used in vivo and in vitro mouse
models and found that implantation of LCM3, LCM4 and LCM6.1
in the peritoneum (rapid throughput model) or under the skin
(subchronic model) induced little inflammation in the
peritoneum and at the implantation sites, respectively. LCM6.1
scaffold induced more collagen fibers in the implantation site
compared to LCM3 and LCM4, which is likely to be related to its
faster degradation. This is consistent with previous studies
showing that degradation products might cause undesired
effects via local pH changes causing inflammation.21 Cellular
immune assays revealed that LCM3, LCM4 and LCM6.1 were
unable to stimulate or inhibit splenocytes upon primary
stimulation indicating that these polymers are not toxic. Three
immunological assays were performed to assess the
immunogenicity and allergenicity of the scaffolds. The in vitro
assays provide information on cytotoxicity, the i.p. response
provides in vivo data on the inflammation and the cytokine
milieu, while the s.c. reaction is long-term and provides
information on the longevity of the inflammation and capacity to
induce fibrosis. Our results support differences in inflammation
caused by the LCMs in the calvarium experiments, with LCM3 and
LCM4 but not LCM6.1 associated with inflammatory cell
infiltrates at 12 weeks. While our i.p. and s.c. results demonstrate
that these polymers are not highly immunologically reactive, they
do appear to induce minimal inflammation in the bone, which is
necessary for bone healing.12, 13, 52, 53 To ensure optimal bone
repair, additional factors should be used in conjunction with the
scaffolds. This is further supported with clinically relevant, Vitoss
that is a successful bone graft material, because it contains
bovine collagen type I that activates inflammation and OCs and
OBs required for bone healing.54, 55
The LCM scaffolds were designed for mechanical support and
stability at the tissue site until new bone is fully matured and able
to withstand mechanical load. Additionally, LCM scaffolds were
intended to degrade and be resorbed at a controlled rate to allow
in vivo formation of the new bone tissue.56 Optimal degradation
kinetics of scaffolds used for bone lesion healing remains
unknown and requires further research. Ideally, the optimal
polymer scaffold material should degrade and resorb at the same
rate as tissue growth into the implant so it can be replaced with
natural bone. PLA and PCL have been approved by the Food and
Drug Administration and are suitable for cartilage and bone
implants.26 Importantly, their degradation and mechanical
profiles can be tuned based on monomers ratio within their
copolymer. They commonly require 1–3 years for complete
degradation and their copolymers degrade faster than the
homopolymers, depending on the LA to CL ratio26. An approach
to achieve scaffolds with controlled degradation rates that fit
specific biomedical application demands may be to use
copolymers of two polymers with different degradation
kinetics.57
It is advantageous to use an elastic and soft material to
fabricate mechano-active scaffolds that can be used under cyclic
mechanical strain. Jeong et al.58, 59 synthesized very flexible
scaffolds based on copolymers of poly(glycolide-co-ɛ-
caprolactone) and PLCL. Those scaffolds maintained a recovery of
approximately 96% for two weeks under cyclic tensile strain (5 to
20%) in PBS.59 Degradation in biological systems was validated by
a non-biological in vitro assessment of degradation. LCM3
scaffolds revealed lower rate of mass loss compared with LCM4
and LCM6.1 (Fig. 7A), which was attributed to differences in
LA/CL ratio between LCM3, 4 and 6.1 scaffold materials. LA/CL
ratio for LCM3, LCM4 and LCM6.1 was 16/4, 18/2 and 9/1
respectively.27 Degradation time, the required time for complete
resorption, of PDLLA is approximately half of that for PCL.60-62
Therefore, the increase in LA content would lead to a higher
degradation rate. This explains the lower rate of mass loss for
LCM3 in comparison with LCM4 and LCM6.1. However, LCM4 and
LCM6.1 scaffolds contain the same LA/CL ratio, LCM6.1 degraded
faster than LCM4. This was attributed to the difference in their
initial molecular weight, ca. 1059 and 1822 g mol-1 for LCM6.1
and LCM4 respectively.27 The difference in degradation rates
among LCM scaffolds was also supported by optical images of the
scaffold throughout the degradation period (Fig. 7B). LCM6.1
disintegrated into fragments by day 69, while LCM3 and 4
scaffolds remained intact till the end of the degradation study,
which was ascribed to the fast degradation rate of LCM6.1
composition. The scaffolds lost ca. 20 – 35% on their initial weight
throughout the degradation period, however the pH of the
degradation medium remained at neutral levels (7.4 ± 0.1) as a
result of the buffering capability of PBS, gradual mass loss of the
scaffolds and replacing the medium in a weekly basis.
Compressive properties of these scaffolds are mainly
dependent on their compositions, specifically their LA/CL ratio,
as all scaffolds have approximately similar porosity and pore
sizes.27 Elastic modulus for PCL is approximately five-fold lower
than PDLLA.60, 61 Consequently, it was expected that mechanical
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properties of the scaffolds would decrease as the CL content
increased within their copolymer. Bramfeldt et al.63
demonstrated that rates of degradation and mechanical loss of
PLCL copolymer increased gradually as the amount of LA changed
from 0 to 70%.
Faster degradation means more inflammation and more tissue
damage over the long term. A good correlation was observed
between in vitro and in vivo findings. LCM6.1 scaffolds showed
faster degradation rate compared to LCM3 and 4 and
consequently, revealed the least evidence for early stages of new
bone formation. Such validated in vitro assays address the 3Rs
research directed towards reducing animal experimentation with
predictable in vitro assays and suggest that they are useful for
pre-clinical assessment of bone repair biomaterials.
Conclusions
Our study focused on a novel biomimetic, biodegradable two-
photon engineered PLCL repeating 3D Schwarz P minimal surface
unit cell copolymer scaffold for the orthopedic surgeon to use for
pain relief and to promote the repair of large non-union bone
fractures. An integrated, multidisciplinary platform combining
expertise in bone biology, immunology and materials science is a
robust strategy which includes: 1) an in vitro evaluation of OBs
and OCs and an in vivo mouse calvarial defect model, 2) in vitro
and in vivo evaluation of inflammatory, immune and allergic
reactions to biomaterials, and 3) in vitro degradation and
mechanical compression and strength studies. Our results
indicate that these copolymers will perform well in the clinic for
bone repair because they can be tailor-made for exact fit in large
bone lesions, the scaffolds with the optimal copolymer
composition are immunologically compatible, allow for normal
OB and OC function and promote bone healing. Moreover, these
scaffolds have mechanical properties designed in consultation
with surgeons to have at least 20% recoverable compression for
fitting them into bone fracture sites. The degradation studies in
vitro agree with in vivo observations and indicate that they
degrade in a suitable period which is sufficient for physiological
bone replacement. This study illustrates an important new
biomaterial with a strategy for pre-clinical evaluation of
biomaterials developed for bone repair.
Conflicts of interest
There are no conflicts to declare.
Acknowledgements
The authors wish to thank our colleagues at the Institute for
Bioprocessing and Analytical Measurement Techniques for
providing the samples as part of the EC FP7 InnovaBone project
and thank Drs. Serena Best and Sahar Kazemi for the critical
reading of the manuscript. This research project has received
funding from the European Union’s Seventh Framework
Programme (FP7/2007–2013) under grant agreement no.
263363. This work was supported by the Engineering and Physical
Sciences Research Council [grant number EP/K029592/1]; and the
EPSRC Centre for Innovative Manufacturing in Medical Devices
(MeDe Innovation).
References
1. E. Garcia-Gareta, M. J. Coathup and G. W. Blunn, Bone,
2015, 81, 112-121.
2. R. Yunus Basha, T. S. Sampath Kumar and M. Doble,
Mater. Sci. Eng. C Mater. Biol. Appl. , 2015, 57, 452-463.
3. I. Dumic-Cule, M. Pecina, M. Jelic, M. Jankolija, I.
Popek, L. Grgurevic and S. Vukicevic, Int. Orthop., 2015,
39, 1005-1011.
4. M. Bumbasirevic, M. Stevanovic, V. Bumbasirevic, A.
Lesic and H. D. Atkinson, Int. Orthop., 2014, 38, 1277-
1282.
5. J. A. Goulet, L. E. Senunas, G. L. DeSilva and M. L.
Greenfield, Clin. Orthop. Relat. Res., 1997, 76-81.
6. Z. S. Ai-Aql, A. S. Alagl, D. T. Graves, L. C. Gerstenfeld
and T. A. Einhorn, J. Dent. Res., 2008, 87, 107-118.
7. E. Tsiridis, N. Upadhyay and P. Giannoudis, Injury,
2007, 38 S11-25.
8. K. Merritt and J. J. Rodrigo, Clin. Orthop. Relat. Res.,
1996, 326, 71-79.
9. L. C. Gerstenfeld, D. M. Cullinane, G. L. Barnes, D. T.
Graves and T. A. Einhorn, J. Cell. Biochem., 2003, 88,
873-884.
10. X. Li, R. J. Quigg, J. Zhou, J. T. Ryaby and H. Wang, J. Cell.
Biochem., 2005, 95, 189-205.
11. C. N. Medine, F. Khan, S. Pernagallo, R. Zhang, O. Tura,
M. Bradley and D. C. Hay, in Biomaterials and stem cells
in regenerative medicine, eds. M. Ramalingam, S.
Ramakrishna and S. Best, 2012, pp. 1-30.
12. H. C. Pape, R. Marcucio, C. Humphrey, C. Colnot, M.
Knobe and E. J. Harvey, J. Orthop. Trauma, 2010, 24,
522-525.
13. O. Bastian, J. Pillay, J. Alblas, L. Leenen, L. Koenderman
and T. Blokhuis, J. Leukoc. Biol., 2011, 89, 669-673.
14. D. G. Tamay, T. Dursun Usal, A. S. Alagoz, D. Yucel, N.
Hasirci and V. Hasirci, Frontiers in Bioengineering and
Biotechnology, 2019, 7.
15. D. W. Hutmacher, Biomaterials, 2000, 21, 2529-2543.
16. B. Dhandayuthapani, Y. Yoshida, T. Maekawa and D. S.
Kumar, Int J Polym Sci, 2011, 2011, 1-19.
17. P. A. Gunatillake and R. Adhikari, Eur. Cells Mater.,
2003, 5, 1-16.
18. B. D. Ulery, L. S. Nair and C. T. Laurencin, J Polym Sci B
Polym Phys, 2011, 49, 832-864.
19. R. Sartoneva, K. Kuismanen, M. Juntunen, S.
Karjalainen, M. Hannula, L. Kyllönen, J. Hyttinen, H.
Huhtala, K. Paakinaho and S. Miettinen, R Soc Open Sci,
2018, 5, 180811-180811.
20. K. K. Moncal, D. N. Heo, K. P. Godzik, D. M. Sosnoski, O.
D. Mrowczynski, E. Rizk, V. Ozbolat, S. M. Tucker, E. M.
Gerhard, M. Dey, G. S. Lewis, J. Yang and I. T. Ozbolat,
Journal of Materials Research , 2018, 33, 1972-1986.
21. S. Lyu and D. Untereker, Int. J. Mol. Sci., 2009, 10, 4033-
4065.
22. Biomaterial fabrication and processing handbook ,
Taylor and Francis Group, CRC Press, 2008.
Journal Name ARTICLE
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 11
Please do not adjust margins
Please do not adjust margins
23. O. Al-Ketan, R. Rezgui, R. Rowshan, H. Du, N. X. Fang
and R. K. Abu Al-Rub, Advanced Engineering Materials,
2018, 20, 1800029.
24. M. Malinauskas, P. Danilevicius and S. Juodkazis, Opt.
Express, 2011, 19, 5602-5610.
25. A. P. Moreno Madrid, S. M. Vrech, M. A. Sanchez and
A. P. Rodriguez, Materials Science and Engineering: C ,
2019, 100, 631-644.
26. J. Holmbom, A. Sodergard, E. Ekholm, M. Martson, A.
Kuusilehto, P. Saukko and R. Penttinen, J. Biomed.
Mater. Res. A, 2005, 75, 308-315.
27. R. M. Felfel, L. Poocza, M. Gimeno-Fabra, T. Milde, G.
Hildebrand, I. Ahmed, C. Scotchford, V. Sottile, D. M.
Grant and K. Liefeith, Biomed. Mater.,2016, 11, 1-14.
28. R. M. Felfel, D. Gupta, A. Z. Zabidi, A. Prosser, C. A.
Scotchford, V. Sottile and D. M. Grant, Materials &
Design, 2018, 160, 455-467.
29. R. M. Felfel, L. Poocza, M. Gimeno-Fabra, T. Milde, G.
Hildebrand, I. Ahmed, C. Scotchford, V. Sottile, D. M.
Grant and K. Liefeith, Biomedical Materials, 2016, 11,
015011.
30. N. Takahashi, T. Akatsu, N. Udagawa, T. Sasaki, A.
Yamaguchi, J. M. Moseley, T. J. Martin and T. Suda,
Endocrinology, 1988, 123, 2600-2602.
31. A. D. Bakker and J. Klein-Nulend, in Bone Research
Protocols, eds. M. Helfrich and S. Ralston, Humana
Press, 2012, vol. 816, pp. 19-29.
32. F. Meyer, J. Wardale, S. Best, R. Cameron, N. Rushton
and R. Brooks, J. Orthop. Res., 2012, 30, 864-871.
33. K. Changi, B. Bosnjak, C. Gonzalez-Obeso, R. Kluger, J.
C. Rodriguez-Cabello, O. Hoffmann and M. M. Epstein,
J. Biomed. Mater. Res. A, 2018, 106, 924-934.
34. K. S. Jones, Semin. Immunol., 2008, 20, 130-136.
35. D. M. Higgins, R. J. Basaraba, A. C. Hohnbaum, E. J. Lee,
D. W. Grainger and M. Gonzalez-Juarrero, Am. J.
Pathol., 2009, 175, 161-170.
36. ISO, BS EN ISO 10993-13: Biological evaluation of
medical devices. Identification and quantification of
degradation products from polymeric medical devices ,
2010.
37. Y. Jung, S. H. Kim, Y. H. Kim and S. H. Kim, Biomed.
Mater., 2009, 4, 1-7.
38. S. Torquato, S. Hyun and A. Donev, Phys. Rev. Lett.,
2002, 89, 1-4.
39. Y. Jung and S. Torquato, Phys. Rev. E Stat. Nonlin. Soft
Matter Phys., 2005, 72, 1-8.
40. C. Zong, D. T. Xue, W. J. Yuan, W. Wang, D. Shen, X. M.
Tong, D. Y. Shi, L. Y. Liu, Q. A. Zheng, C. Y. Gao and J. F.
Wang, Eur. Cells Mater., 2010, 20, 109-120.
41. T. B. Ren, J. Ren, X. Z. Jia and K. F. Pan, J. Biomed.
Mater. Res. A, 2005, 74A, 562-569.
42. A. Cipitria, J. C. Reichert, D. R. Epari, S. Saifzadeh, A.
Berner, H. Schell, M. Mehta, M. A. Schuetz, G. N. Duda
and D. W. Hutmacher, Biomaterials, 2013, 34, 9960-
9968.
43. D. Barbieri, H. Yuan, A. S. Ismailoglu and J. D. de Bruijn,
Tissue Eng Part A, 2017, 23, 1310-1320.
44. S. J. Roberts, L. Geris, G. Kerckhofs, E. Desmet, J.
Schrooten and F. P. Luyten, Biomaterials, 2011, 32,
4393-4405.
45. W. R. Walsh, R. A. Oliver, C. Christou, V. Lovric, E. R.
Walsh, G. R. Prado and T. Haider, PLoS One, 2017, 12,
1-21.
46. K. Chatterjee, S. Lin-Gibson, W. E. Wallace, S. H.
Parekh, Y. J. Lee, M. T. Cicerone, M. F. Young and C. G.
Simon, Biomaterials, 2010, 31, 5051-5062.
47. G. L. Jones, A. Motta, M. J. Marshall, A. J. El Haj and S.
H. Cartmell, Biomaterials, 2009, 30, 5376-5384.
48. A. S. Mao, J. W. Shin and D. J. Mooney, Biomaterials,
2016, 98, 184-191.
49. Y. R. Shih, K. F. Tseng, H. Y. Lai, C. H. Lin and O. K. Lee,
J. Bone Miner. Res., 2011, 26, 730-738.
50. N. D. Evans, C. Minelli, E. Gentleman, V. LaPointe, S. N.
Patankar, M. Kallivretaki, X. Chen, C. J. Roberts and M.
M. Stevens, Eur. Cells Mater., 2009, 18, 1-14.
51. G. Hulsart-Billstrom, J. I. Dawson, S. Hofmann, R.
Muller, M. J. Stoddart, M. Alini, H. Redl, A. El Haj, R.
Brown, V. Salih, J. Hilborn, S. Larsson and R. O. C.
Oreffo, Eur. Cells Mater., 2016, 31, 312-322.
52. I. H. Kalfas, Neurosurg. Focus, 2001, 10, 1-4.
53. K. Schmidt-Bleek, H. Schell, N. Schulz, P. Hoff, C. Perka,
F. Buttgereit, H. D. Volk, J. Lienau and G. N. Duda, Cell
Tissue Res., 2012, 347, 567-573.
54. M. P. Bostrom and D. A. Seigerman, HSS J., 2005, 1, 9-
18.
55. C. Van Hoff, J. B. Samora, M. J. Griesser, M. K. Crist, T.
J. Scharschmidt and J. L. Mayerson, Am. J. Orthop.
(Belle Mead NJ), 2012, 41, 20-23.
56. J. Henkel, M. A. Woodruff, D. R. Epari, R. Steck, V. Glatt,
I. C. Dickinson, P. F. Choong, M. A. Schuetz and D. W.
Hutmacher, Bone research, 2013, 1, 216-248.
57. V. Guarino, F. Causa, P. Taddei, M. di Foggia, G.
Ciapetti, D. Martini, C. Fagnano, N. Baldini and L.
Ambrosio, Biomaterials, 2008, 29, 3662-3670.
58. S. I. Jeong, J. H. Kwon, J. I. Lim, S. W. Cho, Y. Jung, W. J.
Sung, S. H. Kim, Y. H. Kim, Y. M. Lee, B. S. Kim, C. Y. Choi
and S. J. Kim, Biomaterials, 2005, 26, 1405-1411.
59. S. I. Jeong, B. S. Kim, Y. M. Lee, K. J. Ihn, S. H. Kim and
Y. H. Kim, Biomacromolecules, 2004, 5, 1303-1309.
60. P. B. Maurus and C. C. Kaeding, Oper. Tech. Sports
Med., 2004, 12, 158-160.
61. J. C. Middleton and A. J. Tipton, Biomaterials, 2000, 21,
2335-2346.
62. M. A. Woodruff and D. W. Hutmacher, Prog. Polym.
Sci., 2010, 35, 1217-1256.
63. H. Bramfeldt, P. Sarazin and P. Vermette, J. Biomed.
Mater. Res. A, 2007, 83, 503-511.
